MNG1001
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.378
- PANCREAS_BETA_CELLS+0.362
- G2M_CHECKPOINT+0.343
- MYC_TARGETS_V2+0.329
- ALLOGRAFT_REJECTION+0.169
- MITOTIC_SPINDLE+0.164
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.159
- HEDGEHOG_SIGNALING+0.143
- ANGIOGENESIS+0.108
- SPERMATOGENESIS+0.072
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.412
- OXIDATIVE_PHOSPHORYLATION-0.367
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- PEROXISOME-0.324
- PROTEIN_SECRETION-0.305
- HEME_METABOLISM-0.294
- CHOLESTEROL_HOMEOSTASIS-0.291
- IL6_JAK_STAT3_SIGNALING-0.267
- ADIPOGENESIS-0.263
- FATTY_ACID_METABOLISM-0.255
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JVW2JJ39 | high-grade glioma | — | 0.844 |
| 2 | BS_XG0DBWVT | high-grade glioma | — | 0.825 |
| 3 | BS_N4B1SZZH | medulloblastoma | — | 0.817 |
| 4 | MBCProject_1334_T1_RNA | — | C | 0.802 |
| 5 | BS_JT82QGXF | medulloblastoma | — | 0.801 |
| 6 | MNG459 | — | — | 0.800 |
| 7 | BS_44A3ES23 | medulloblastoma | — | 0.797 |
| 8 | BS_C41DJZ1F | high-grade glioma | — | 0.792 |
| 9 | BS_SD8YBRBR | high-grade glioma | — | 0.790 |
| 10 | BS_TA9WP4TH | medulloblastoma | — | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.378 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.362 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.343 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.329 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.169 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.164 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.159 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.143 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.108 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.072 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.071 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.062 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.009 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.003 | Inavolisib | — uncovered |